PARIS--(BUSINESS WIRE)--Regulatory News:
Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced the introduction of its needle-based Cellvizio solution for use in lung cancer and respiratory diseases applications during the European Respiratory Society (ERS) International Congress 2018, being held September 15-19, in Paris, France.
During the congress there will be an oral presentation from Dr. Lizzy Wijmans, Amsterdam, Netherlands on the topic of needle-based Confocal Laser Endomicroscopy (nCLE) for Diagnosing Malignant Pleural Mesothelioma, showing positive results for Cellvizio. There are also five additional presentations using needle-based Confocal Laser Endomicroscopy across different indications showing the growing momentum of the Cellvizio platform in pulmonology.
“Our presence and robust presentation schedule at this year’s ERS congress reflects the introduction of our ground-breaking needle-based endomicroscopy solution in the lung disease space. These presentations add to the growing body of evidence for Cellvizio as a valuable tool for the detection, diagnosis and treatment management of a range of pulmonary diseases,” said Sacha Loiseau, Ph.D., Founder and Chief Executive Officer of Mauna Kea Technologies. “In particular, the unique ability of Cellvizio to get to the core of pulmonary lesions through a needle is a unique offer which could dramatically improve the management of patients with suspicion of lung cancer. This opens up important possibilities for Cellvizio in the management of the second most prevalent cancer worldwide.”
Featured Presentations include:
-
Needle Based Confocal Laser Endomicroscopy (nCLE) for Diagnosing
Malignant Pleural Mesothelioma
Session 77; Presentation OA496
Oral Presentation: Pleural disease – diagnosis, monitoring and management
Date, Time: Sunday, September 16 at 11:30-11:45 a.m. CET
Room: 7.3Q
Presenting Author: Dr. Lizzy Wijmans, Amsterdam, Netherlands
-
Confocal Laser Endomicroscopy (CLE) as a Guidance Tool for
Transbronchial Lung Cryobiopsies in ILD
Session 249; Presentation OA2163
Oral Presentation: Interventional pulmonology highlights in 2018 – latest innovations
Date, Time: Monday, September 17 at 10:45-11:00 a.m. CET
Room: 7.3P
Presenting Author: Dr. Lizzy Wijmans, Amsterdam, Netherlands
-
Probe-based Confocal Laser Endomicroscopy in Differential Diagnosis
of Interstitial Lung Disease (ILD)
Session 350; Presentation PA3377
Poster Discussion: Cryobiopsy in interstitial lung disease (ILD)
Date, Time: Monday, September 17; at 14:45-16:45 p.m. CET
Room: 7.2C
Presenting Author: Dr. Igor Mamenko, St. Petersburg, Russian Federation
-
First Procedure: Confocal Endoscopy Lesions
Session 372
Oral Session: Pulmonary Endoscopy – Lung cancer and the pleural diseases
Date, Time: Tuesday, September 18; at 8:30-9:00 a.m. CET
Room: 7.3A
Session Chair and Presenting Author: Prof. Luc Thiberville, Rouen, France
-
Confocal Laser Endomicroscopy (CLE) for Differentiating the
Underlying Cause of Ground Glass Opacities in ILD Patients
Session 388; Presentation PA3655
Poster Discussion: CTD-ILD and hypersensitivity pneumonitis – from the bench to the bedside
Date, Time: Tuesday, September 18 at 8:30-10:30 a.m. CET
Room: 7.2B
Presenting Author: Dr. Lizzy Wijmans, Amsterdam, Netherlands
-
Probe-based Confocal Laser-Endomicroscopy Imaging of Differential
Auto-Fluorescence of Alveolar Macrophages in Diffuse Lung Diseases
Session 466; Presentation PA4801
Thematic poster: Back to basics and translational research in idiopathic interstitial pneumonias
Date, Time: Tuesday, September 18 at 12:50-14:40 p.m. CET
Room: TP-45
Presenting Author: Prof. Dr. Kazuyoshi Imaizumi, Toyoake, Japan
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product, Cellvizio®, has received clearance/approval in a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico. For more information on Mauna Kea Technologies, visit www.maunakeatech.com
Disclaimer
This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities. Such forward looking statements are based on assumptions that Mauna Kea Technologies considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward- looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of Mauna Kea Technologies registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on April 27, 2018 under number R.18-0429 and available on the Company's website (www.maunakeatech.com), and to the development of economic situation, financial markets, and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Mauna Kea Technologies that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for, Mauna Kea Technologies shares in any country.
